Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy.

Centre Léon Bérard, Lyon, France.

Survival: monthsCountry:France
Toxiciy Grade:5City/State/Province:Lyon
Treatments:ChemotherapyHospital:Centre Léon Bérard
Drugs:Journal:Link
Date:Mar 2011

Description:

Patients:
This study involved 56 men with metastatic castration-resistant prostate cancer. The median patient age was 67.7 years.

Treatment:
Patients in this study were treated with the chemotherapy agents etoposide and carboplatin.

Toxicities:
One treatment-related death due to febrile neutropenia was reported. Grade 3-4 toxicities included neutropenia (65.5% of patients), thrombocytopenia (32.7%), and anemia (27.3%).

Results:
The median progression-free survival was 2.9 months and the median overall survival was 9.6 months.

Correspondence: Dr. A. Flechon; email: [email protected]



Back